MABp1

Drug Profile

MABp1

Alternative Names: CA-18C3; CV-18C3; Hutruo; MAB-p1; RA-18C3; T2-18C3; Xilonix

Latest Information Update: 16 Jun 2017

Price : $50

At a glance

  • Originator XBiotech
  • Developer Hellenic Institute for the Study of Sepsis; XBiotech
  • Class Anti-inflammatories; Antihyperglycaemics; Antineoplastics; Antipsoriatics; Antirheumatics; Monoclonal antibodies; Vascular disorder therapies
  • Mechanism of Action Angiogenesis inhibitors; Immunomodulators; Interleukin 1 alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Colorectal cancer
  • Phase III Cachexia
  • Phase II Acne vulgaris; Hidradenitis suppurativa; Non-small cell lung cancer; Plaque psoriasis; Pyoderma; Type 2 diabetes mellitus; Vascular restenosis
  • Phase I Haematological malignancies

Most Recent Events

  • 12 Jun 2017 XBiotech terminates the phase III XCITE trial in Colorectal cancer in USA, United Kingdom, Netherlands, Poland, Hungary, Belgium, Czech Republic, Spain, Austria, and Germany
  • 01 Jun 2017 Additional efficacy data from a phase III trial in Colorectal cancer released by XBiotech
  • 19 May 2017 CHMP gives negative opinion on approval of MABp1 for Colorectal cancer in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top